{"schema_version":"secwatch.filing_event.v1","accession":"0001818331-23-000041","form_type":"8-K","ticker":"WGS","cik":"0001818331","company_name":"GeneDx Holdings Corp.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.820779+00:00","generated_at":"2026-06-15T09:47:09.836913+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"GeneDx Q1 2023 pro forma revenue $40.7M (+7% YoY); exome revenue up 22% to $22.4M; reaffirms FY guidance","bullets":["Pro forma revenue from continuing ops $40.7M, up 7% YoY; whole exome/genome test revenue $22.4M, up 22%.","Adjusted gross margin from continuing ops 34%; total company cash burn improved 31% YoY to $58.8M.","Net loss ($60.4)M; adjusted net loss ($48.9)M, improvement of 23% YoY.","Reaffirms FY2023 guidance: revenue $205-220M, cash burn $95-110M for continuing ops, profitable in 2025.","Completed $150M public offering; appointed Devin K. Schaffer as General Counsel."],"urls":{"canonical":"https://secwatch.observer/filing/0001818331-23-000041","json":"https://secwatch.observer/filing/0001818331-23-000041.json","markdown":"https://secwatch.observer/filing/0001818331-23-000041.md","text":"https://secwatch.observer/filing/0001818331-23-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818331/000181833123000041/0001818331-23-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818331/000181833123000041/smfr-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:47:09.836913+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7d52f6622f8eead6b37831effb36916c2812a759","claim":"GeneDx Holdings Corp. reported the first quarter of 2023 results: revenue $40.7 million. Guidance reaffirmed.","evidence_excerpt":"GeneDx Reports First Quarter 2023 Financial Results and Business Highlights Generated $40.7 million in first quarter 2023 pro forma revenue from continuing operations, representing a 7% increase year over year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818331/000181833123000041/0001818331-23-000041-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2023"},{"label":"Revenue","value":"$40.7 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}